Document:

<PAGE>

                                                                    EXHIBIT 10.2

                             IMS HEALTH INCORPORATED

                         XPONENT DATA LICENSE AGREEMENT

         AGREEMENT, dated as of this _____ day of _____________, 2000,
("Effective Date") by and between IMS Health Incorporated (hereinafter "IMS"), a
Delaware corporation with an address at 200 Nyala Farms, Westport, Connecticut
06880, and the Interactive Marketing Division of Synavant Inc., (hereinafter
"Licensee"), a Delaware corporation, with an address at One Broad Avenue,
Fairview, New Jersey 07022.

                                    RECITALS

         WHEREAS, IMS is principally engaged in providing information services
to the pharmaceutical industry and, in connection therewith, collects data from
pharmacies through various third parties relating to prescription transactions
and prescribers;

         WHEREAS, Licensee, on behalf of its customers, is principally engaged
in providing direct marketing of pharmaceutical promotion to prescribers in the
United States and circulation management of healthcare publications in the
United States; and

         WHEREAS, IMS desires to license certain data to Licensee in accordance
with and subject to the terms set forth in this Agreement;

         NOW, THEREFORE, in consideration of the foregoing and of the mutual
promises herein contained, the parties agree as follows:

1.       DEFINITIONS. For purposes of this Agreement, the following terms shall
         have the meanings specified:

         a.       "affiliate" of Licensee means any Person which now or in the
                  future controls, is controlled by or is under common control
                  with Licensee.
         b.       "Agency" means an agency engaged by a Manufacturer to develop
                  and/or implement a marketing campaign for one or more of such
                  Manufacturer's Legended Drugs.
         c.       "Association" means a professional association, comprised of
                  members in a health care-related profession, which is,
                  pursuant to the terms of Paragraph 8(a), identified by IMS as
                  licensing data to IMS that is incorporated into certain
                  elements of the Data.
         d.       "Contract Year" means each 12-month period commencing on
                  September 1 and ending on August 30 during the term of this
                  Agreement.

<PAGE>

         e.       "Desktop Media" means prescription pads, medical forms and
                  other similar promotional material which are provided to
                  Prescribers at a nominal charge or without charge, and which
                  contain advertising relating to one or more Legended Drugs.
         f.       "Healthcare Company" means (i) a manufacturer of Legended
                  Drugs or any Person licensed by such a manufacturer to market
                  and sell Legended Drugs ("Manufacturer") or an Agency;
                  provided, however, that neither a wholesaler of Legended
                  Drugs, a pharmacy, nor a Person providing mail service
                  prescription drug programs shall be deemed a "Manufacturer";
                  (ii) a manufacturer of medical supplies and/or diagnostic
                  equipment, or any person licensed by such a manufacturer to
                  market and sell medical supplies and/or diagnostic equipment;
                  (iii) a publisher of single or multi-sponsored journals which
                  are devoted to medicine, health care or veterinary subjects
                  ("Journals"); (iv) a publisher of Desktop Media, (v) a sponsor
                  of continuing medical education ("CME") seminars, conferences
                  or courses or a publisher of CME materials or (vi) a pharmacy
                  benefits management company or "PBM".
         g.       "Legended Drugs" means drugs which under Federal or state law
                  require the written prescription of a doctor, osteopath or
                  other individual who has the authority to prescribe Legended
                  Drugs.
         h.       "Materials" means (i) information, including promotional
                  materials and solicitation materials sent to a Prescriber, all
                  of which relate to one or more Legended Drugs or
                  over-the-counter drugs of a Manufacturer or relate to medical
                  supplies and/or diagnostic equipment marketed by a Healthcare
                  Company, (ii) surveys or questionnaires sent to a Prescriber
                  which either seek information relating to the prescribing or
                  practice profile of such Prescriber or the use by such
                  Prescriber of medical supplies or diagnostic equipment;
                  provided, however, that the use of such surveys or
                  questionnaire shall be subject to the terms of Paragraph 7(a)
                  hereof, (iii) Journals, (iv) Desktop Media, or (v)
                  information, including promotional materials, solicitation
                  materials or course materials, relating to CME.
         i.       "Data" means certain data provided by IMS from its Xponent
                  -Registered Trademark- Plantrak-TM- and Xponent -Registered
                  Trademark- Profiler-TM- information services and other
                  services as further described on EXHIBIT 1 hereto.
         j.       "Person" means any natural person, corporation, business
                  trust, joint venture, association, company, firm, partnership,
                  government entity or other entity.
         k.       "Prescriber" means a doctor, osteopath, dentist or other
                  individual with an address in the United States who has the
                  authority to prescribe Legended Drugs.

2.       LICENSE GRANT
         IMS hereby grants to Licensee a non-transferable and non-exclusive
         license, without the right to grant sublicenses, to Data for use solely
         in accordance with the terms of Paragraphs 4 and 5 hereof and subject
         to the other terms and conditions of this Agreement and only for the
         uses as specified in Exhibit 3. The licenses granted herein are not
         exclusive and nothing contained herein shall prohibit or restrict IMS
         from

<PAGE>

         licensing, selling or otherwise transferring Data or any other
         information to any other Person or from using Data or any other
         information for its own purposes.

3.       DATA
         IMS shall provide the Data to Licensee in accordance with the
         operational procedures set forth on EXHIBIT 2 hereto. IMS will use its
         reasonable efforts to process Data in an accurate and complete manner.
         IMS will promptly notify Licensee of any material inaccuracies in such
         Data which become known to IMS in accordance with IMS's then applicable
         internal procedures for data quality assurance.

4.       USE OF DATA
         Subject to the other terms and conditions of this Agreement, the Data
         licensed hereunder shall be used by Licensee solely for the uses and
         purposes listed on Exhibit 3:

5.       CONDITIONS APPLICABLE TO USE OF DATA
         a.       The delivery of any Materials, Legended Drug samples or
                  over-the-counter drug samples in connection with Paragraph 4
                  may be made by U.S. Postal Service, other common carrier,
                  telegram, telephone, facsimile transmission, modem or other
                  means; provided, however, that under no circumstances shall
                  delivery of any of such Materials or Legended Drug samples be
                  accomplished by (i) any employee of a Manufacturer, including
                  but not limited to any pharmaceutical sales representative of
                  such Manufacturer, or (ii) any Person engaged by a
                  Manufacturer to call on Prescribers on behalf of such
                  Manufacturer in connection with the marketing of one or more
                  Legended Drugs.
         b.       The use of any list of Prescribers selected by Licensee from
                  the Data pursuant to the terms of Paragraph 4 shall be limited
                  to a specific one-time use or a single marketing program
                  conducted by Licensee for a Healthcare Company or any renewal
                  or repeat of such program by Licensee; provided, however, that
                  with the exception of Limited Data, and the retention of
                  Historical Data as provided under Paragraph 11(c), any Data,
                  or any information derived from such Data, contained in or
                  identified with such list may only be used in a manner
                  permitted hereunder for a period not to exceed ninety (90)
                  days, after which such Data must be destroyed. In the event
                  any Data or any information derived therefrom is copied or
                  incorporated into any database, data bank or any file or
                  listing containing any data not provided pursuant to the terms
                  of this Agreement, such database, data bank, file or listing,
                  as the case may be, shall be and remain subject to all of the
                  terms and conditions of this Agreement.
         c.       Except as provided under Paragraphs 5(d), 5(e) and 18 hereof,
                  Licensee shall retain the Data and any information derived
                  therefrom only within the internal confines of Licensee's own
                  organization. The parties hereto acknowledge and agree that
                  the preceding sentence is fundamental to this Agreement and
                  Licensee shall not design programs or provide multiple copies
                  of lists to a Healthcare Company which taken together would
                  result in either directly or indirectly

<PAGE>

                  avoiding the restriction contained in the preceding sentence.
                  Licensee shall not provide any Data to any third party,
                  including but not limited to a Healthcare Company or any
                  affiliate of Licensee, except as specifically set forth below:
                  (1)      if a Healthcare Company engages a third party to
                           provide lettershop or similar services in connection
                           with sending Materials to Prescribers (a
                           "Lettershop"), Limited Data may be provided by
                           Licensee to the Lettershop; provided, however,
                           Licensee enters into a written agreement with such
                           Lettershop in accordance with Paragraph 5(f)(1) of
                           this Agreement. The Lettershop shall be required to
                           return Limited Data to Licensee or the Healthcare
                           Company, as the case may be, within ten (10) calendar
                           days of the earlier of completion or termination of
                           the respective order for services.
                  (2)      in the event Licensee selects a list of Prescribers
                           from the Data for use in connection with providing
                           Materials or Legended Drug samples to certain of such
                           Prescribers on behalf of a Manufacturer, Licensee may
                           provide Limited Data to such Manufacturer for the
                           sole purpose of permitting such Manufacturer to
                           notify its sales representatives of Prescribers
                           within each sales representative's territory who were
                           sent such Materials or Legended Drug samples;
                           provided, however, Licensee sends a purchase order to
                           such Manufacturer or enters into a written agreement
                           with such Manufacturer in accordance with Paragraph
                           5(f)(2) of this Agreement; and provided further that
                           Limited Data derived in whole or in part from Data is
                           not provided to a Manufacturer any more frequently
                           than once in any thirty (30) day period.
                  (3)      In connection with the delivery to a Prescriber of
                           any sample of a Manufacturer's Legended Drugs in
                           response to a solicitation made pursuant to Paragraph
                           4, Licensee may provide Limited Data to such
                           Manufacturer, and such Manufacturer shall be
                           permitted to retain Limited Data relating to the
                           recipients of such Legended Drug samples solely for
                           purposes of compliance with any applicable state and
                           Federal laws, including but not limited to laws
                           relating to the distribution of Legended Drug
                           samples, such period of retention in each instance to
                           be limited to the longest period of time necessary to
                           comply with any such laws.

         d.       Licensee may provide the following types of information
                  derived from the Data to a Healthcare Company that is a
                  prospective customer for a specific service of Licensee that
                  involves the selecting of lists of Prescribers, derived from
                  the Data, for the uses permitted by the terms of Paragraph 4
                  of this Agreement, solely for purposes of promoting such
                  service provided such information does not identify individual
                  Prescribers and is not summarized by and/or identified with
                  any geographic area or unit, including but not limited to zip
                  codes, counties, states or sales territories, but aggregates
                  Prescribers only in the following manner:
                  (1)      by Prescriber specialty, the total number of
                           Prescribers per specialty contained in the Data,
                           and/or

<PAGE>

                  (2)      by prescribing level, in quintiles or deciles.
         e.       Licensee may provide to a Healthcare Company for whom Licensee
                  has provided a product or service which uses Data as permitted
                  under Paragraph 4 in connection with a single marketing
                  program, the total number of Prescribers that were sent
                  Materials or responded to Materials from Licensee, as the case
                  may be, with respect to such program.
         f.       If at any time Licensee provides any Limited Data or any
                  information derived from such Data to:

                  (1)      a Lettershop, Licensee shall enter into a written
                           agreement with such Lettershop, which agreement
                           shall, among other things, contain such terms and
                           conditions as are necessary or desirable to prohibit
                           such Lettershop from making any use of such Limited
                           Data and/or information in a manner which is
                           inconsistent with the terms and conditions of this
                           Agreement. Such terms and conditions, at a minimum,
                           shall include:
                           (a)  a provision stating that the Limited Data is
                                being provided to the Lettershop solely for the
                                limited purpose set forth in Paragraph 5(c)(1);
                           (b)  terms and conditions which reflect the
                                obligations and restrictions contained in
                                Paragraphs 5(a), 5(b), 5(c)(1), 5(g), 5(h), 6, 7
                                and 8;
                           (c)  a provision stating that the use of Limited Data
                                is limited to a specific one-time use or use in
                                connection with a single marketing program, as
                                the case may be; and
                           (d)  a provision stating that IMS Health Incorporated
                                is an intended third party beneficiary to the
                                agreement between Licensee and such Lettershop.
                                In the event a Lettershop fails to comply with
                                such an agreement, Licensee shall promptly
                                notify an appropriate representative of such
                                Lettershop in writing of such failure, with a
                                copy to IMS, within five business days after
                                Licensee knows or reasonably suspects such
                                failure. Licensee shall promptly provide IMS
                                with a copy of any correspondence between
                                Licensee and such Lettershop relating to such
                                failure. IMS shall have a right to bring an
                                action as an intended third party beneficiary to
                                enforce the terms and conditions of the
                                agreement between Licensee and such Lettershop
                                to the extent such terms and conditions are
                                required by the terms of this Paragraph 5(f). In
                                the event IMS does not have rights as an
                                intended third party beneficiary to bring an
                                action as contemplated in this Paragraph 5(f),
                                Licensee agrees to be liable for any breach by
                                such Lettershop of such agreement.
                  (2)      a Manufacturer, Licensee shall either send an order
                           form to such Manufacturer or enter into a written
                           agreement with such Manufacturer which order form or
                           agreement, as the case may be, shall, among other
                           things, contain such terms and conditions as are
                           necessary or desirable to prohibit such Manufacturer
                           from making any use of such Limited Data

<PAGE>

                           and/or information in a manner which is inconsistent
                           with the terms and conditions of this Agreement. Such
                           terms and conditions, at a minimum, shall include:
                           (a)  a provision stating that the Limited Data is
                                being provided to the Manufacturer solely for
                                one or both of the limited purposes set forth in
                                Paragraphs 5(c)(2) and (3);
                           (b)  terms and conditions which reflect the
                                obligations and restrictions contained in
                                Paragraphs 5(a), 5(b), 5(c)(2) and/or 5(c)(3),
                                as the case may be, 5(g), 5(h), 6, 7 and 8;
                           (c)  a provision stating that the use of Limited Data
                                is limited to a specific one-time use and/or use
                                in connection with a single marketing program;
                           (d)  a provision stating that such Manufacturer is
                                not permitted to store the Limited Data in any
                                database or otherwise use the Limited Data to
                                target the calling activity of its sales
                                representatives on Prescribers; and
                           (e)  a provision stating that IMS Health Incorporated
                                is an intended third party beneficiary to the
                                agreement between Licensee and such
                                Manufacturer.

                           In the event a Manufacturer fails to comply with such
                           an agreement, Licensee shall promptly notify an
                           appropriate representative of such Manufacturer in
                           writing of such failure, with a copy to IMS, within
                           five business days after Licensee knows or suspects
                           such failure. Licensee shall promptly provide IMS
                           with a copy of any correspondence between Licensee
                           and such Manufacturer relating to such failure. IMS
                           shall have a right to bring an action as an intended
                           third party beneficiary to enforce the terms and
                           conditions of the agreement between Licensee and such
                           Manufacturer to the extent such terms and conditions
                           are required by the terms of this Paragraph 5(f). In
                           the event IMS does not have rights as an intended
                           third party beneficiary to bring an action as
                           contemplated in this Paragraph 5(f), Licensee agrees
                           to be liable for any breach by such Manufacturer of
                           such agreement.
                  Such agreements shall specify the intended uses of such
                  Limited Data in sufficient detail so that it may be determined
                  whether such use is in compliance with the terms and
                  conditions of this Agreement. Such agreements shall be
                  available to IMS in connection with any inspection which IMS
                  may perform pursuant to Paragraph 17 of this Agreement.
         g.       In connection with any use of Data, under no circumstances
                  shall any of such Data or any information derived therefrom be
                  disclosed to a Prescriber or to any other Person except as
                  expressly provided herein.
         h.       Notwithstanding anything to the contrary contained herein,
                  under no circumstances shall any Data or Limited Data be
                  provided by Licensee to any Person which has one or more lines
                  of business engaged in the licensing, selling

<PAGE>

                  or providing of access to data, information or databases in
                  competition with IMS or any Subsidiary ("Competing Company"),
                  or any Person controlling, controlled by or under common
                  control with a Competing Company, including but not limited to
                  the Competing Companies listed on Exhibit 4; provided,
                  however, that nothing herein shall preclude Licensee, a
                  Manufacturer or an Agency from engaging a Lettershop for the
                  delivery of Materials in accordance with the terms of
                  Paragraph 5(a) and in connection therewith, providing Limited
                  Data to such Lettershop in accordance with Paragraph 5(c)(1),
                  provided Licensee complies with the terms of Paragraph
                  5(f)(1).

         As used in this Paragraph, "Limited Data" shall mean Data limited to
         the following fields of information: Prescriber name and Prescriber
         address to which the Material or Legended Drug sample was sent or to be
         sent. Limited Data shall also include Association Data, provided
         Licensee has an appropriate license with respect to such Data and
         further provided the use of such Association Data and if applicable,
         the disclosure of such Association Data, is permitted under the terms
         of such license.

6.       PROHIBITED USES OF DATA
         IMS does not grant, and Licensee does not receive, any title or other
         interest in the Data or any information derived therefrom, including
         but not limited to the Limited Data, except for those rights granted
         explicitly in this Agreement; all rights not expressly granted to
         Licensee are reserved to IMS. Without limiting the generality of the
         foregoing, under no circumstances shall Licensee use, or permit any
         other Person to use, Data received by Licensee in connection with this
         Agreement, or any information derived therefrom, including but not
         limited to the Limited Data, in any manner which:
         a.       is contrary to the terms of this Agreement or is otherwise not
                  expressly permitted by the terms of this Agreement;
         b.       will violate any law or regulation by such use;
         c.       will violate the contractual restrictions of any Association
                  identified by IMS pursuant to Paragraph 7(a) governing the use
                  of such Association's data incorporated within the Data in
                  effect at the time of the use of such Data, unless an
                  authorized representative of IMS provides Licensee with
                  written notice that such Data is no longer subject to the
                  restrictions of such Association's agreement;
         d.       results in any analysis of the Data, or any information
                  derived therefrom, which analysis (i) results in the
                  disclosure to one or more Persons of any information regarding
                  the mathematical algorithms, formulas, processes, or
                  projection or statistical methods used by IMS to produce any
                  of the Data, (ii) is used or made available for use to promote
                  or aid in the promoting of any data or information which is
                  not derived from the Data, or (iii) seeks to demonstrate that
                  the Data, or any information derived therefrom, is inferior to
                  any other data, attempts to show any deficiency in such Data
                  or information, or otherwise makes statements detrimental to
                  IMS concerning such Data or information;
         e.       results in the selection of Prescribers from which a
                  Manufacturer, an Agency, Licensee or any other Person solicits
                  information on practice profiles and/or

<PAGE>

                  prescribing activity for the purpose of developing a database
                  of practice and prescribing profiles on individual
                  Prescribers, except for the solicitation of such information
                  for the benefit of (i) a single Manufacturer or (ii) a single
                  Healthcare Company that is a manufacturer or marketer of
                  medical supplies and/or diagnostic equipment;
         f.       applies one or more mathematical algorithms, formulas or
                  processes to any of the Data for the purpose of estimating or
                  projecting any new data or information;
         g.       results in the reverse engineering or disassembling of any of
                  the Data;
         h.       enhances, benchmarks, validates, compares with, authenticates,
                  verifies, supplements, or modifies any data, products or
                  services of Licensee or any other party except as expressly
                  provided in this Agreement;
         i.       facilitates, authorizes or otherwise expressly or tacitly
                  permits the incorporation of the Data, or any information
                  derived therefrom, in any sales force automation system,
                  electronic territory management system, customer relationship
                  management system, or any other similar system used by sales
                  representatives for call reporting and management of sales
                  information for their respective territories, except as
                  expressly provided in Paragraph 5(c)(2);
         j.       facilitates, authorizes or otherwise expressly or tacitly
                  permits the use of any Data, or any information derived
                  therefrom, by a Manufacturer for use in connection with the
                  compensation or management of such Manufacturer's sales
                  force(s); or
         k.       facilitates, authorizes or otherwise expressly or tacitly
                  permits the use of any Data, or any information derived
                  therefrom, by a Manufacturer for targeting of Prescribers by
                  the sales representatives of such Manufacturer.

7.       ASSOCIATION DATA
         a.       IMS may identify to Licensee in writing certain elements of
                  some or all of the Data which incorporates information
                  licensed to IMS by an Association ("Association Data"). In
                  addition to the terms and conditions of this Agreement,
                  Licensee agrees to treat each element of Association Data in
                  accordance with the terms of the respective Association
                  agreement then in effect between IMS and such Association. To
                  the extent that any term of such an Association agreement then
                  in effect is more restrictive concerning the use or disclosure
                  of Association Data than the terms contained in this Agreement
                  concerning the use or disclosure of Data, then the terms of
                  such Association Agreement shall control, but only with
                  respect to the use or disclosure, as the case may be, by
                  Licensee of Association Data.
         b.       In the event IMS identifies Association Data pursuant to
                  Paragraph 7(a) above and Licensee fails to maintain the
                  requisite license with the Association licensing such data to
                  IMS which would permit Licensee, at a minimum, a right to use
                  the Association Data provided hereunder in the manner
                  contemplated herein, IMS shall have no further requirement to
                  provide such Association Data under the terms of this
                  Agreement until such time as Licensee obtains such a license.

<PAGE>

         c.       By way of example, and not by way of limitation, any element
                  of Data identifying:
                  (1)      the Medical Education number of the Prescriber is
                           derived from the American Medical Association's
                           ("AMA") Physician Professional Data and shall remain
                           subject to the terms and conditions of the applicable
                           AMA agreement then in effect between IMS and the AMA.
                  (2)      the American Osteopathic Association ("AOA") number
                           of the Prescriber is derived from the AOA's data
                           files and shall remain subject to the terms and
                           conditions of the applicable AOA agreement then in
                           effect between IMS and the AOA.

8.       CONFIDENTIALITY
         Licensee hereby acknowledges that the Data are proprietary to IMS
         (collectively "Confidential Information"), agree to protect the
         proprietary and confidential nature of such Confidential Information
         and in connection therewith, will prohibit any access to or copying or
         disclosure of any of the Confidential Information during the term of
         this Agreement and after termination of this Agreement, except (a) that
         access to and disclosure of Confidential Information may be provided to
         those employees of Licensee, in connection with the uses permitted
         Licensee as described in Exhibit 3 who require same to carry out such
         uses, and (b) as expressly permitted under Paragraphs 5(c), (d) and (e)
         of this Agreement. Licensee and any such other persons who receive
         access to or disclosure of Confidential Information pursuant to the
         preceding sentence shall maintain the strict confidentiality of such
         Confidential Information in the same manner as Licensee maintains the
         confidentiality of its own confidential information, and Licensee will
         not disclose such Confidential Information except as expressly provided
         herein. In the event any of such other persons fail to comply with the
         confidentiality obligations contained in this Paragraph 8, Licensee
         shall promptly notify an appropriate representative of such person in
         writing of such failure, with a copy to IMS, within five business days
         after Licensee knows or suspects such failure. Licensee shall promptly
         provide IMS with a copy of any responses from such person to Licensee's
         notification. IMS shall have a right to bring an action as an intended
         third party beneficiary to enforce the terms and conditions of the
         agreement between Licensee and such person with respect to obligations
         of confidentiality. In the event IMS does not have rights as an
         intended third party beneficiary to bring an action as contemplated in
         this Paragraph 8, Licensee agrees to be liable for any breach by such
         person of such agreement. Licensee agrees that it will not ever, either
         during the term of this Agreement or after its termination, assert that
         Data are not, were not or will not be proprietary to IMS and subject to
         copyright held by IMS with the exception of elements of Association
         Data which is proprietary to the respective Association and subject to
         copyright held by such Association.

9.       REPRESENTATIONS AND WARRANTIES

<PAGE>

         IMS represents and warrants that it has the right and authority to
         license the Data to Licensee under this Agreement. EXCEPT AS EXPRESSLY
         STATED IN THE PRECEDING SENTENCE OR PARAGRAPH 3, IMS MAKES NO WARRANTY
         OR REPRESENTATION, EXPRESS OR IMPLIED, AS TO THE DATA (INCLUDING BUT
         NOT LIMITED TO ANY WARRANTY OF MERCHANTABILITY OF SUCH DATA OR ITS
         FITNESS FOR LICENSEE'S PARTICULAR PURPOSE) AND FURTHER MAKES NO
         WARRANTY OR REPRESENTATION, EXPRESS OR IMPLIED, AS TO THE ACCURACY OR
         COMPLETENESS OF THE DATA.

10.      LIMITATION OF LIABILITY
         IMS's entire liability and Licensee's exclusive remedy for IMS's
         failure to abide by the accuracy and completeness requirements of
         Paragraph 3 shall be for IMS to endeavor to correct, in accordance with
         IMS's then applicable operating procedures for data quality assurance,
         any such non-conformance which has been reported by Licensee to IMS in
         writing in a timely manner in accordance with EXHIBIT 2.
         Notwithstanding any injunctive relief which Licensee may be entitled
         to, IMS shall not be liable for any indirect, consequential, punitive,
         incidental or special damages to person, property or business which may
         be caused by any use, failure to provide or unavailability of Data or
         any breach by IMS of its obligations hereunder (even if IMS has been
         advised of the possibility of such damages).

11.      TERM/TERMINATION
         a.       The term of this Agreement shall be for a three year period
                  commencing on the date first written above. Notwithstanding
                  the foregoing, IMS shall have the right to terminate this
                  Agreement on thirty (30) days advance written notice to
                  Licensee:
                  (1)      if Licensee becomes insolvent, voluntarily files a
                           petition under any federal or state bankruptcy law
                           for itself, has an involuntary petition filed under
                           any federal or state bankruptcy law against it which
                           is not removed within thirty (30) days of filing,
                           ceases operations for at least thirty (30) days with
                           the intent of winding up Licensee's business, or
                           otherwise publicly announces the termination of its
                           operations and/or substantially all the products
                           relating to the licenses granted herein;
                  (2)      upon the sale of Licensee, whether by merger,
                           consolidation, the sale of its stock or by the sale
                           of all or substantially all of its assets to a
                           Competing Company or any Person controlling,
                           controlled by or under common control with a
                           Competing Company; or
                  (3)      if Licensee or any affiliate of Licensee develops or
                           comes into possession of data which is substantially
                           similar to the Data or Licensee or any affiliate of
                           Licensee acquires the right, by license, purchase or
                           otherwise, to data which is substantially similar to
                           the Data.
                  As used in Paragraph 11(a)(3), data which is "substantially
                  similar to the Data" shall include but not be limited to any
                  data or information (a) consisting of or

<PAGE>

                  derived from a number of prescription transactions in any
                  calendar month which number is greater than or equal to
                  one-twentieth of the number of prescription transactions as
                  estimated by IMS's National Prescription Audit for such
                  calendar month, or (b) which Licensee or any affiliate of
                  Licensee claims is the functional or statistical equivalent of
                  data that consists of or is derived from a number of
                  prescription transactions in any calendar month which number
                  is greater than or equal to one-twentieth of the number of
                  prescription transactions as estimated by IMS's National
                  Prescription Audit for such calendar month. However, data
                  shall not be considered "substantially similar to the Data"
                  for any data received from a pharmaceutical Manufacturer for
                  use by Licensee solely to provide services to such
                  Manufacturer.
         b.       In the event of the termination of this Agreement:
                  (1)      Licensee shall deliver all Data, and any information
                           derived therefrom, in its possession or control to
                           IMS within ten (10) days of such termination, except
                           as otherwise expressly provided in Paragraph 11(c).
                  (2)      for any period during which Data, or any information
                           derived therefrom, remains in the possession or
                           control of Licensee after termination of this
                           Agreement, such Data and information shall remain
                           subject to the restrictions contained in this
                           Agreement, including but not limited to those
                           restrictions contained in Paragraphs 4, 5, 6, 7, and
                           8.
                  This provision shall not be construed to limit survival of any
                  other provision which also survives the termination of this
                  Agreement by the express or implied terms of such provision.
         c.       In connection with the selection of a list of Prescribers for
                  a use permitted pursuant to Paragraph 4, Licensee is
                  authorized to maintain, for a period of three years (or longer
                  to the extent required by law) from the date following the
                  termination of this Agreement, historical files containing the
                  following data elements from Data: physician name, physician
                  address used in connection with a delivery made in accordance
                  with the terms of this Agreement, Prescriber identification
                  number and Prescriber specialty (collectively "Historical
                  Data"). Such Historical Data may be maintained for such three
                  year period only for the following purposes: (i) servicing a
                  possible Legended Drug product recall pursuant to applicable
                  regulations promulgated by a government agency whereby notices
                  are delivered to Prescribers chosen from a list produced by
                  Licensee under the terms of this Agreement to whom samples of
                  such Legended Drugs were sent, (ii) recreating a delivery made
                  on behalf of a Healthcare Company pursuant to the terms of
                  this Agreement in which an error was made either by Licensee
                  and/or the Healthcare Company, as the case may be, which error
                  is the sole reason for recreating such delivery, or (iii)
                  responding to an audit or written request of a governmental
                  agency for information on the recipients of a Legended Drug
                  sample delivered in the fulfillment of a request by a
                  Prescriber in response to a solicitation made pursuant to
                  Paragraphs 4(a), 4(b) or 4(d). Within thirty (30)

<PAGE>

                  days following the end of such period, the Historical Data for
                  such deliveries will be deleted from Licensee's possession and
                  control.

12.      DEFAULT
         a.       A "Default" shall exist hereunder by Licensee if Licensee
                  fails in any material respect to be in compliance with the
                  terms of Paragraphs 2, 4, 5, 6, 7 or 8 (an "Event of Default")
                  and such failure, if curable, is not cured within ten (10)
                  calendar days following notice of such failure from IMS.
         b.       If IMS alleges an Event of Default by Licensee, and Licensee
                  in good faith disputes the occurrence of such Event of
                  Default, IMS agrees to continue to provide Data hereunder
                  until such dispute is resolved by the parties or by a
                  determination through arbitration as provided in Paragraph 16,
                  without prejudice to any remedies available to IMS.

13.      CERTAIN REMEDIES
         a.       If the sale of any product or the rendering of any service or
                  the license of any Data gives rise to an Event of Default
                  pursuant to Paragraph 2 or 4 of this Agreement, then IMS shall
                  receive from Licensee an amount equal to the aggregate of the
                  gross revenues recognized from the sale of such product or the
                  fees charged in connection with the rendering of such service
                  or the licensing of such Data.
         b.       Two or more Events of Defaults hereunder, whether or not
                  cured, shall entitle IMS, in its sole discretion, to
                  immediately terminate this Agreement upon written notice to
                  Licensee; provided, however, that each such Event of Default
                  is acknowledged in writing by Licensee and/or is finally
                  determined by arbitration pursuant to Paragraph 16 of this
                  Agreement.
         c.       Nothing herein shall be construed as limiting IMS's rights and
                  remedies in the event of a breach of this Agreement by
                  Licensee, whether or not such breach is cured. The rights and
                  remedies set forth in Paragraphs 11 and 13 of this Agreement
                  are in addition to any other rights or remedies which
                  otherwise may be available, in law or in equity.

14.      FORCE MAJEURE
         Licensee agrees that IMS shall not be deemed to have breached this
         Agreement or to be liable for any damages caused by failure to perform
         or by delay in rendering performance hereunder arising out of any
         occurrence or contingency beyond its reasonable control, including but
         not limited to, (a) flood, earthquake, fire, war, strikes, labor
         unrest, riot, civil commotion, power or communication line failure,
         computer equipment failure or operational failure, (b) failure of
         independent contractors under agreement with IMS to perform or a delay
         in such performance, failures, delays or restrictions of sources from
         which information or data is obtained, or failure of performance by
         Licensee, or (c) prohibition(s) or restriction(s) imposed by applicable
         regulatory authority, the judgment, ruling or order of a court or
         agency of competent jurisdiction, or the enactment of or change in any
         law or regulation.

<PAGE>

15.      ADDITIONAL AGREEMENTS
         a.       IMS and Licensee each agree to keep the terms of this
                  Agreement in confidence and not disclose them to any other
                  Person, except for those terms of the Agreement required to be
                  disclosed (i) pursuant to federal or state laws or regulations
                  including securities laws and their related disclosure
                  requirements, (ii) pursuant to judicial or arbitration orders
                  and proceedings, (iii) as may be required to perform their
                  obligations under this Agreement, or (iv) to each of IMS's and
                  Licensee's legal and financial representatives who need to
                  know such terms solely for the purpose of providing legal and
                  financial advice to each such party, respectively. This
                  provision shall not prohibit either party from disclosing the
                  existence of this Agreement or that IMS is a data source.
         b.       Upon the request of IMS, the President of Licensee (or in the
                  event the President of Licensee is not responsible for the
                  day-to-day business of Licensee, then the General Manager of
                  Licensee or such other person who has overall responsibility
                  for the day-to-day business of Licensee) shall provide IMS
                  with a written statement certifying that, after due inquiry,
                  Licensee has complied in all material respects with Licensee's
                  obligations under the provisions of Paragraphs 2, 4, 5, 6, 7
                  and 8 of this Agreement for the past Contract Year, except as
                  noted therein.
         c.       Under no circumstances shall this Agreement be construed as
                  placing any affirmative obligation on IMS, express or implied,
                  to collect or continue to collect any data or information from
                  any third party, including but not limited to pharmacy data
                  from which the Data is derived ("Source Data"). In the event
                  IMS determines, in its sole judgment and discretion, to cease
                  collecting any Source Data which will result in a substantial
                  reduction in the amount of, or cessation in, the Data
                  delivered hereunder, IMS will provide written notice of such
                  at least ninety (90) days prior to the date on which such
                  Source Data collection will cease, specifying the date or
                  dates at which IMS will cease collecting such Source Data and
                  the approximate number of prescriptions that will not be
                  included in the Data in the ensuing twelve months as a result
                  (the "IMS Notice"). In such event, IMS shall incur no
                  liability to Licensee in connection therewith and, in the
                  event IMS ceases to collect all of such Source Data, then this
                  Agreement shall automatically terminate and be of no further
                  force and effect immediately upon the last delivery of Data to
                  Licensee. A "substantial reduction" means a reduction in the
                  aggregate amount of prescriptions comprising the Source Data
                  for use in connection with the delivery of Data hereunder in
                  excess of twenty-five percent (25%) when compared with the
                  aggregate amount of prescriptions comprising the Source Data
                  available to IMS for use in connection with the delivery of
                  Data for the same calendar quarter period in the immediately
                  prior year.
         d.       IMS and Licensee acknowledge that a data supplier to IMS may
                  request that some or all of its data be restricted in such a
                  manner as to prevent IMS from providing such data, or
                  information derived therefrom, to Licensee ("Data Supplier
                  Request"). In the event of a Data Supplier Request, IMS may,
                  at its sole option,

<PAGE>

                  enter into an agreement or arrangement or continue an
                  agreement or arrangement, as the case may be, which
                  accommodates such Request; provided, however, IMS, prior to
                  the acceptance of such an agreement or arrangement, uses
                  reasonable efforts to persuade such data supplier to provide
                  its data without such restriction. For purposes of this
                  Paragraph 15(d), IMS shall be deemed to have used "reasonable
                  efforts" if IMS, in connection with its negotiations with such
                  data supplier, makes a bona fide attempt to persuade such data
                  supplier to provide its data to IMS without such restriction;
                  provided, however, under no circumstances shall IMS have any
                  obligation to increase the amounts paid, or to be paid, to
                  such data supplier in exchange for the elimination of such
                  restriction.
         e.       IMS agrees that, upon the request of Licensee, IMS shall
                  negotiate in good faith with Licensee for a period of not more
                  than 30 days with respect to the acquisition by Licensee of
                  IMS's Xponent-Registered Trademark- information services in
                  certain European countries. In the event that the parties
                  have not entered into a definitive agreement with respect
                  to such acquisition at the end of such 30-day period, IMS
                  shall have no further obligations pursuant to this
                  Section 15(e). The parties acknowledge and agree that nothing
                  in this Section 15(e) shall create a binding obligation on IMS
                  or Licensee to consummate such an acquisition or shall
                  constitute any expression of the parties' intent or agreement
                  with respect to the terms of any such acquisition; any such
                  obligation and such terms will be created and expressed only
                  by a definitive agreement or agreements, if any, negotiated
                  and entered into by the parties.

16.      ARBITRATION
         a.       Each party shall designate a project manager to coordinate
                  such party's activities under this Agreement. Such project
                  managers shall also, when necessary, confer in order to
                  resolve problems or disputes that may arise in connection with
                  each party's performance hereunder. If the project managers
                  cannot resolve such problems or disputes, such problems or
                  disputes shall be referred to each party's respective senior
                  management including, if necessary, its President for
                  discussion and resolution.
         b.       Subject to Paragraph 16(d), any controversy or claim arising
                  out of or relating to this Agreement, and which cannot be
                  resolved in accordance with the procedure set forth in the
                  preceding paragraph, shall be submitted to arbitration before
                  a panel of three (3) arbitrators. The arbitrators shall be
                  selected and the arbitration conducted in accordance with the
                  Commercial Rules of the American Arbitration Association. An
                  award shall be conclusive and binding if concurred in by two
                  (2) of the arbitrators, and judgment upon the award rendered
                  by the arbitrators may be entered in any court having
                  jurisdiction thereof. The arbitrators shall be required to
                  deliver a written decision setting forth their findings of
                  fact and basis for their award. The arbitrators' award shall
                  provide for the payment of the arbitrators' expenses and fees,
                  together with other expenses incurred in the conduct of the
                  arbitration proceeding other than legal fees and expenses.
                  However, the

<PAGE>

                  arbitrators shall award the prevailing party reasonable
                  attorneys' fees and other expenses incurred in the arbitration
                  proceeding in the event that the arbitrators determine that
                  either party acted in bad faith in connection with either
                  asserting a claim or a defense in the arbitration proceeding
                  itself.
         c.       The parties hereby agree to submit to the exclusive personal
                  jurisdiction and venue of the United States District Court for
                  the Eastern District of Pennsylvania for purposes of enforcing
                  the agreement to arbitrate, providing provisional relief
                  pending the award, and entering judgment on the award. If for
                  any reason the aforesaid court does not have subject matter
                  jurisdiction, the parties alternatively agree to submit to the
                  exclusive personal jurisdiction and venue of the applicable
                  court of the Commonwealth of Pennsylvania, County of
                  Montgomery, for the foregoing purposes. Nothing contained in
                  this paragraph shall preclude the arbitrators from granting,
                  where appropriate, injunctive or other provisional relief
                  pending a final award.
         d.       Notwithstanding the provisions of Paragraphs 16(b) and (c),
                  any party hereto may pursue any provisional remedy (including
                  but not limited to preliminary injunctive relief) to enforce
                  its rights hereunder in the courts designated in Paragraph
                  16(c). The parties shall have the right to obtain such
                  provisional injunctive relief from a court of law designated
                  in Paragraph 16(c) pending the determination and award in the
                  arbitration proceeding. The parties may seek injunctive relief
                  either restraining certain conduct or mandating certain
                  conduct. This Paragraph 16(d) shall not be deemed to limit the
                  power of the arbitrators to grant any remedy or relief the
                  arbitrators deem just or reasonable within the scope of this
                  Agreement.
         e.       The parties agree that, immediately upon the designation of
                  the arbitrators, they will request the arbitrators that they
                  set an expedited schedule for the conduct of the arbitration
                  proceeding such that the proceeding is concluded within six
                  months of the date of the filing of a demand for arbitration
                  and that an award shall be rendered within thirty (30) days of
                  the conclusion of the proceeding.

17.      INSPECTION RIGHTS / COOPERATION
         a.       IMS shall have the right to make an inspection of the
                  business, books and records of Licensee upon five (5) days
                  notice to Licensee for the purpose of verifying Licensee's
                  compliance with its obligations pursuant to Paragraphs 2, 4,
                  5, 6, 7 and 8 of this Agreement. Licensee shall maintain
                  business records, books, account information, computer logs
                  and related materials sufficient to permit IMS to verify that
                  Licensee is in compliance with its obligations under the
                  above-referenced Paragraphs.
         b.       Any such inspection of Licensee's books and records shall be
                  performed by IMS's representatives and/or its outside
                  auditors. The costs of such an inspection shall normally be at
                  IMS's expense. However, Licensee shall bear the cost of an
                  inspection if such inspection reveals an Event of Default or
                  any other material breach of the terms of this Agreement.

<PAGE>

18.      MISCELLANEOUS
         a.       The parties hereto are independent contractors engaged in the
                  operation of their own respective businesses. Neither party
                  is, or is to be considered as, the agent or employee of the
                  other for any purpose whatsoever. Neither party has the
                  authority to enter into contracts or assume any obligations
                  for the other party or make any warranties or representations
                  on behalf of the other party. Nothing in this Agreement shall
                  be construed to establish a relationship of co-partners or
                  joint venturers between the parties.
         b.       This Agreement constitutes the entire understanding between
                  the parties and supersedes all proposals, commitments,
                  writings, negotiations and understandings, oral and written,
                  and all other communications between the parties relating to
                  the subject matter of this Agreement.
         c.       IMS may assign all or any portion of this Agreement to an
                  entity which is then an affiliated company and any such
                  affiliated company may assign all or any portion of this
                  Agreement to an entity which is then an affiliated company;
                  provided, however, that any such assignment shall not relieve
                  IMS of its obligations under this Agreement if the assignee
                  fails to perform. This Agreement may not be assigned from
                  Licensee to any other Person, whether by assignment by
                  Licensee, by operation of law or otherwise without the prior
                  written consent of IMS which consent shall not be unreasonably
                  withheld. The sale or transfer of a majority of the
                  outstanding shares of Licensee, or the merger or consolidation
                  of Licensee with any other Person, shall be deemed an -
                  attempt by Licensee to assign its interests in this Agreement
                  which shall first require the prior written consent of IMS.
                  Any assignment not expressly permitted under this Paragraph
                  18(c) or which has not received the written consent of the
                  other party if required herein shall be void.
         d.       Should any part, term or condition hereof be declared illegal
                  or unenforceable or in conflict with any other law, the
                  validity of the remaining portion or provisions of this
                  Agreement shall not be affected thereby, and the illegal or
                  offensive portions of this Agreement shall be and hereby are
                  redrafted to conform with applicable law in a manner which is
                  consistent with the original spirit and intent embodied in the
                  original executed copy of this Agreement, while leaving the
                  remaining portions of this Agreement intact.
         e.       The waiver by either party of a breach or violation hereof or
                  remedy provided herein shall not operate as or be construed to
                  be a waiver of any subsequent breach or violation hereof.
         f.       This Agreement shall be governed by and construed in
                  accordance with the laws of the Commonwealth of Pennsylvania
                  without giving effect to principles of conflicts of law.
         g.       Nothing in this Agreement is intended to benefit and shall not
                  be deemed to benefit any person who is not a party hereto or
                  to create any third party beneficiary rights.

<PAGE>

         h.       All notices pertaining to this Agreement or the performance of
                  either party hereunder shall be sufficient if in writing and
                  sent by Federal Express or other similar overnight courier
                  service with receipted delivery addressed to the other party
                  at the address shown below or to such other address as a party
                  hereto shall supply to the other in writing:

                  If to IMS:

                           IMS Health Incorporated
                           660 W. Germantown Pike
                           Plymouth Meeting, PA  19462
                           Attention:  President

                  With a copy to:

                           IMS Health Incorporated
                           660 W. Germantown Pike
                           Plymouth Meeting, PA  19462
                           Attention:  Law Department

                  If to Licensee:
                           Synavant, Inc.
                           Interactive Marketing Division
                           One Broad Avenue
                           Fairview, NJ  07022
                           Attention:  President

                  With a copy to:
                           Synavant, Inc.
                           3445 Peachtree Road, N.E.
                           Suite 1400
                           Atlanta, GA 30326
                           Attention:  President

                  Such notice shall be effective upon receipt by the other
party.
         i.       Neither party may under any circumstances utilize the name,
                  trademarks, or tradenames of the other, or any names,
                  trademarks, or tradenames so similar as likely to cause
                  confusion, without the prior written notice to, and express
                  written approval of, the other. Notwithstanding the preceding
                  sentence:
                  (1)      Licensee's advertising and other promotional
                           materials for products or services which use any of
                           the Data shall identify IMS as originator of such
                           Data, a copy of which material will be promptly
                           provided to IMS on or before the first release of any
                           such material;
                  (2)      Licensee is hereby granted a non-transferable and
                           non-exclusive license, without the right to grant
                           sublicenses, to use the trademark Xponent in

<PAGE>

                           connection with the advertising and promotion of the
                           Data, as such term is defined in EXHIBIT 1, and
                           Licensee agrees to use such trademark in connection
                           with its advertising and promotion of any products or
                           services which use Data in accordance with the
                           following:
                           (a)  whenever Licensee uses the Xponent trademark in
                                advertising or in any other manner in connection
                                with the Projected Data or any products or
                                services of Licensee which use the Projected
                                Data, Licensee shall clearly indicate IMS's
                                ownership of the trademark;
                           (b)  samples of all literature, stationery, packages,
                                labels and advertising prepared by or for
                                Licensee and intended to be used by Licensee in
                                connection with the use of the Xponent trademark
                                shall be promptly provided to IMS by Licensee on
                                or before the release of such materials;
                           (c)  when using the Xponent trademark, Licensee
                                agrees to comply with all laws pertaining to
                                trademarks in force at any time in the United
                                States, including but not limited to, compliance
                                with marking requirements;
                           (d)  Licensee agrees to comply with any written usage
                                guidelines provided by IMS for use of the
                                Xponent trademark;
                           (e)  Licensee acknowledges (i) IMS's exclusive right,
                                title and interest in and to the Xponent
                                trademark and will not at any time do or cause
                                to be done any act or thing contesting or in any
                                way impairing or tending to impair any part of
                                such right, title and interest, and (ii) use by
                                Licensee of the Xponent trademark shall not
                                create in Licensee's favor any right, title or
                                interest in or to the Xponent-TM- trademark, but
                                that all uses of the Xponent trademark by the
                                Licensee shall inure to the benefit of IMS.
                  (3)      IMS shall have a right to identify to any Persons (i)
                           that Licensee is a licensee of Data from IMS and (ii)
                           those products and services which Licensee may use
                           the Data under the terms of this Agreement.
         j.       Paragraph headings herein are for convenience only and do not
                  control or affect the meaning or interpretation of any terms
                  or provisions of this Agreement.

         IN WITNESS WHEREOF, the parties have executed this Agreement on the
date first written above.

IMS Health Incorporated:                   Synavant Inc.:

By:____________________________            By:__________________________________

Name:__________________________            Name:________________________________

<PAGE>

Title:_________________________            Title:_______________________________

Date: _________________________            Date:  ______________________________<PAGE>
                                                  EXHIBIT 10.3

                             CROSS LICENSE AGREEMENT

         AGREEMENT, dated as of this _____ day of _____________, 2000,
("Effective Date") by and between IMS Health Incorporated (hereinafter "IMS"), a
Delaware corporation with an address at 200 Nyala Farms, Westport, Connecticut
06880, for and on behalf of the Affiliates listed in the Exhibits hereto, and
Synavant Inc. (hereinafter "ST"), a Delaware corporation, with an address at
3445 Peachtree Road, N.E., Suite 1400, Atlanta, Georgia 30326 for and on behalf
of the Affiliates listed in the Exhibits hereto.

                                    RECITALS

         WHEREAS, IMS, among other things, provides information services to the
pharmaceutical industry;

         WHEREAS, ST , among other things, collects and makes commercially
available certain demographic and profiling information on health care
professionals (e.g., doctors, nurses, pharmacists) and health care providers
(e.g., hospitals, pharmacies, clinics) in various countries around the world
("Pharbase Services"); and

         WHEREAS, IMS desires to provide certain health care data to ST for use
in connection with it's Pharbase(TM) Services, and ST desires to provide
information from it's Pharbase Services to IMS for use in it's information
services, all in accordance with and subject to the terms set forth in this
Agreement;

         NOW, THEREFORE, in consideration of the foregoing and of the mutual
promises herein contained, the parties agree as follows:

                             ARTICLE I - DEFINITIONS

For purposes of this Agreement, the following terms shall have the meanings
specified:

1.1      "Affiliate" means any Entity which now or in the future controls, is
         controlled by or is under common control with a party hereto.
1.2      "Contract Year" means each 12-month period commencing on September 1st
         and ending on August 30th during the term of this Agreement.
1.3      "Desktop Media" means prescription pads, medical forms and other
         similar promotional material which are provided to Prescribers at a
         nominal charge or without charge, and which contain advertising
         relating to one or more Legended Drugs.

<PAGE>

1.4      "Entity" means any corporation, business trust, joint venture,
         association, company, firm, partnership, government entity or other
         entity.
1.5      "Healthcare Company" means (i) a manufacturer of Legended Drugs or any
         Person licensed by such a manufacturer to market and sell Legended
         Drugs ("Manufacturer") or an Agency; provided, however, that neither a
         wholesaler of Legended Drugs, a pharmacy, nor a Person providing mail
         service prescription drug programs shall be deemed a "Manufacturer";
         (ii) a manufacturer of medical supplies and/or diagnostic equipment, or
         any person licensed by such a manufacturer to market and sell medical
         supplies and/or diagnostic equipment; (iii) a publisher of single or
         multi-sponsored journals which are devoted to medicine, health care or
         veterinary subjects ("Journals"); (iv) a publisher of Desktop Media, or
         (v) a sponsor of continuing medical education ("CME") seminars,
         conferences or courses or a publisher of CME materials.
1.6      "IMS Data" means certain data from IMS as further described in exhibits
         attached hereto. Each exhibit forms a part of this Agreement. Terms and
         conditions in said exhibit(s) shall supersede any conflicting terms and
         conditions in this Agreement for only the specific IMS Data defined in
         said exhibit(s).
1.7      "Legended Drugs" means drugs which under Federal, provincial, state or
         national law require the written prescription of a doctor, osteopath or
         other individual who has the authority to prescribe Legended Drugs.
1.8      "Materials" means (i) information, including promotional materials and
         solicitation materials sent to a Prescriber, all of which relate to one
         or more Legended Drugs of a Manufacturer or relate to medical supplies
         and/or diagnostic equipment marketed by a Healthcare Company, (ii)
         surveys or questionnaires sent to a Prescriber which either seek
         information relating to the prescribing or practice profile of such
         Prescriber or the use by such Prescriber of medical supplies or
         diagnostic equipment; provided, however, that the use of such surveys
         or questionnaire shall be subject to the terms of Paragraph 7(e)
         hereof, (iii) Journals, (iv) Desktop Media, or (v) information,
         including promotional materials, solicitation materials or course
         materials, relating to CME.
1.9      "Pharbase Data" means certain data from ST as more fully described in
         exhibits attached hereto. Each exhibit forms a part of this Agreement.
         Terms and conditions in said exhibit(s) shall supersede any conflicting
         terms and conditions in this Agreement for only the specific Pharbase
         Data defined in said exhibit(s). In addition, Pharbase Data shall
         include all other demographic and profiling information on health care
         professionals (e.g., doctors, nurses, pharmacists) and health care
         providers (e.g., hospitals, pharmacies, clinics) then in the possession
         or control of ST, or any ST Affiliate, in any country. As any new
         Pharbase Data or new fields of data for existing Pharbase Data
         (collectively "New Data") comes into the possession or control of ST,
         or any ST Affiliate, ST shall notify IMS of such New Data within five
         (5) days following its availability to ST or the applicable ST
         Affiliate, as the case may be, and the Pharbase Data shall include all
         such New Data, without any change in fees, unless otherwise notified by
         IMS to ST or to the applicable ST Affiliate.

<PAGE>

1.10     "Prescriber" means a doctor, osteopath, dentist or other individual
         with an address in the country identified in the applicable exhibits
         who has the authority to prescribe Legended Drugs.

                        ARTICLE II - LICENSE TO IMS DATA

2.1      LICENSE GRANT
         a. IMS hereby grants to ST a non-transferable and non-exclusive license
         to IMS Data for use solely in accordance with the terms of Paragraph
         2.3 hereof and subject to the other terms and conditions of this
         Agreement. The license granted herein is not exclusive and nothing
         contained in this Article II shall prohibit or restrict IMS from
         licensing, selling or otherwise transferring IMS Data or any other
         information to any other person or Entity or from using IMS Data or any
         other information for its own purposes.

         b. Notwithstanding the terms of Paragraph 2.1(a) above, the granting
         and acceptance of each IMS Data license may be by IMS and ST, or an
         Affiliate of either of them, as specified in the applicable exhibit.

2.2      IMS DATA
         IMS shall provide the IMS Data to ST in accordance with the operational
         procedures set forth in the applicable exhibit hereto. IMS will use its
         reasonable efforts to process IMS Data in an accurate and complete
         manner. IMS will promptly notify Licensee of any material inaccuracies
         in such Data which become known to IMS in accordance with IMS's then
         applicable internal procedures for data quality assurance.

2.3      USE OF IMS DATA
         Subject to the other terms and conditions of this Agreement, the IMS
         Data licensed hereunder shall be used by ST solely to update it's
         Pharbase database(s) identified in the applicable schedule (the
         "Authorized Pharbase Databases"); provided, however, any such updated
         Pharbase database may only be used for the following purposes:
         a.       to select, on behalf of a Healthcare Company, a list of
                  Prescribers for the purpose of sending Materials, developed by
                  or on behalf of such Healthcare Company, to certain of such
                  Prescribers;
         b.       in connection with ST 's drug sampling services, to select, on
                  behalf of one or more Manufacturers, a list of Prescribers,
                  which list ST may use solely for the purpose of sending its
                  order form to certain of such Prescribers soliciting a request
                  from each of such Prescribers for a small quantity of Legended
                  Drugs of each of such Manufacturers (a "Form");

<PAGE>

         c.       to select, on behalf of a publisher of Journals or a publisher
                  of Desktop Media, a list of Prescribers for the purpose of
                  determining advertisements to appear in a Journal or in
                  Desktop Media;
         d.       to select, on behalf of a Manufacturer, a list of Prescribers
                  for the purpose of sending Legended Drug samples of such
                  Manufacturer to certain of such Prescribers; or
         e.       for loading into the sales force automation systems of a
                  Manufacturer who is a customer of ST for such systems for use
                  in connection with electronic territory management by or on
                  behalf of such Manufacturer.

2.4.     CONDITIONS APPLICABLE TO USE OF IMS DATA
         a.       Except as expressly provided in Paragraph 2.3, ST shall retain
                  the IMS Data and any information derived therefrom only within
                  the internal confines of ST 's own organization. ST shall not
                  provide any IMS Data to any third party, including but not
                  limited to a Healthcare Company or any affiliate of ST, except
                  as commingled with the Pharbase Data.
         b.       Notwithstanding anything to the contrary contained herein,
                  under no circumstances shall any IMS Data or any information
                  derived therefrom be provided by ST to any person or Entity
                  which has one or more lines of business engaged in the
                  licensing, selling or providing of access to data, information
                  or databases in competition with IMS or any Affiliate
                  ("Competing Company"), or any person or Entity controlling,
                  controlled by or under common control with a Competing
                  Company, including but not limited to the Competing Companies
                  listed on Exhibit 3; provided, however, that nothing herein
                  shall preclude a Manufacturer from engaging the services of a
                  third party (including a Competing Company) to provide
                  services which require access to the Pharbase Data and in
                  connection therewith, ST authorizes access to Pharbase Data.

2.5.     PROHIBITED USES OF IMS DATA
         IMS does not grant, and ST does not receive, any title or other
         interest in the IMS Data or any information derived therefrom,
         including but not limited to the Limited Data, except for those rights
         granted explicitly in this Agreement; all rights not expressly granted
         to ST are reserved to IMS. Without limiting the generality of the
         foregoing, under no circumstances shall ST use, possess, distribute, or
         permit any other person or Entity to use, IMS Data received by ST in
         connection with this Agreement, or any information derived therefrom,
         including but not limited to the Limited Data, in any manner which:
         a.       is contrary to the terms of this Agreement or is otherwise not
                  expressly permitted by the terms of this Agreement;
         b.       will violate any law or regulation by such use;
         c.       will violate the contractual restrictions of any third party
                  identified by IMS pursuant to Paragraph 4.1 governing the use
                  of such third party's data incorporated within the IMS Data in
                  effect at the time of the use of such IMS Data, unless an

<PAGE>

                  authorized representative of IMS provides ST with written
                  notice that such IMS Data is no longer subject to the
                  restrictions of such third party's agreement;

         d.       results in any analysis of the IMS Data, or any information
                  derived therefrom, which analysis (i) results in the
                  disclosure to a person or Entity of any information regarding
                  the mathematical algorithms, formulas, processes, or
                  statistical methods used by IMS to produce any of the IMS
                  Data, (ii) is used or made available for use to promote or aid
                  in the promoting of any data or information which is not
                  derived from the IMS Data (other than the Pharbase Data), or
                  (iii) seeks to demonstrate that the IMS Data, or any
                  information derived therefrom, is inferior to any other data,
                  attempts to show any deficiency in such IMS Data or
                  information, or otherwise makes statements detrimental to IMS
                  or any of it's Affiliates concerning such IMS Data or
                  information;
         e.       results in the reverse engineering or disassembling of any of
                  the IMS Data; or
         f.       enhances, benchmarks, validates, compares with, authenticates,
                  verifies, supplements, or modifies any IMS Data except as
                  expressly provided in this Agreement.

                     ARTICLE III - LICENSE TO PHARBASE DATA

3.1      LICENSE GRANT
         a. ST hereby grants to IMS a non-transferable and non-exclusive license
         to Pharbase Data for use solely in accordance with the terms of
         Paragraph 3.3 hereof and subject to the other terms and conditions of
         this Agreement. The licenses granted herein are not exclusive and
         nothing contained in this Article III shall prohibit or restrict ST
         from licensing, selling or otherwise transferring Pharbase Data or any
         other information to any other Person or from using Pharbase Data or
         any other information for its own purposes.

         b. Notwithstanding the terms of Paragraph 3.1(a) above, the granting
         and acceptance of each Pharbase Data license may be by IMS and ST, or
         an Affiliate of either of them, as specified in the applicable exhibit.

3.2      PHARBASE DATA
         ST shall provide the Pharbase Data to IMS in accordance with the
         operational procedures set forth in the applicable exhibit hereto. ST
         will use its reasonable efforts to process Pharbase Data in an accurate
         and complete manner. ST will promptly notify IMS of any material
         inaccuracies in such Pharbase Data which become known to ST in
         accordance with ST 's then applicable internal procedures for data
         quality assurance.

3.3      USE OF PHARBASE DATA
         Subject to the other terms and conditions of this Agreement, the
         Pharbase Data licensed hereunder shall be used by IMS solely for the
         following purposes: (a) to update its

<PAGE>

         prescriber databases; (b) to update its sales, prescription and market
         research databases used principally in connection with the delivery of
         sales management information services and market research services
         (collectively the updated data described in (a) and (b) is hereby
         referred to as the "Updated Databases"), and (c) to create derivative
         works and license the Updated Databases and such derivative works to
         third parties in connection with the delivery of one or more of the
         services of IMS.

3.4.     CONDITIONS APPLICABLE TO USE OF PHARBASE DATA
         a.       Except as expressly provided in Paragraph 3.3, IMS shall
                  retain the Pharbase Data and any information derived therefrom
                  only within the internal confines of IMS 's own organization.
                  IMS shall not provide any Pharbase Data to any third party,
                  including but not limited to a Healthcare Company or any
                  affiliate of ST, except as commingled with IMS information or
                  services.
         b.       Notwithstanding anything to the contrary contained herein,
                  under no circumstances shall any uncommingled Pharbase Data be
                  provided by IMS to any person or Entity which has one or more
                  lines of business engaged in: (i) sales force automation and
                  customer relationship management systems, (ii) implementation,
                  integration and consulting services relating to the foregoing,
                  (iii) direct marketing services (including direct mail and
                  interactive telephone marketing), and (iv) drug sample
                  accountability and distribution, in each case relating to the
                  pharmaceutical, biotechnology, diagnostics, medical / surgical
                  supply and health care industries, in competition with ST or
                  any Affiliate ("Competing Company"),or any person or Entity
                  controlling, controlled by or under common control with a
                  Competing Company, including but not limited to the Competing
                  Companies listed on Exhibit 4; provided, however, that nothing
                  herein shall preclude a Manufacturer from engaging the
                  services of a third party (including a Competing Company) to
                  provide services which require access to the Pharbase Data and
                  in connection therewith, IMS authorizes access to Pharbase
                  Data.

3.5.     PROHIBITED USES OF PHARBASE DATA
         ST does not grant, and IMS does not receive, any title or other
         interest in the Pharbase Data or any information derived therefrom,
         except for those rights granted explicitly in this Agreement; all
         rights not expressly granted to IMS are reserved to ST. Without
         limiting the generality of the foregoing, under no circumstances shall
         IMS use, or permit any other person or Entity to use, Pharbase Data
         received by IMS in connection with this Agreement, or any information
         derived therefrom, in any manner which:
         a.       is contrary to the terms of this Agreement or is otherwise not
                  expressly permitted by the terms of this Agreement;
         b.       will violate any law or regulation by such use;
         c.       will violate the contractual restrictions of any third party
                  identified by ST pursuant to Paragraph 4.1 governing the use
                  of such third party's data incorporated within the Pharbase
                  Data in effect at the time of the use of such Pharbase Data,

<PAGE>

                  unless an authorized representative of ST provides IMS with
                  written notice that such Pharbase Data is no longer subject to
                  the restrictions of such third party's agreement;
         d.       results in any analysis of the Pharbase Data, or any
                  information derived therefrom, which analysis (i) results in
                  the disclosure to one or more Persons of any information
                  regarding the mathematical algorithms, formulas, processes, or
                  statistical methods used by ST to produce any of the Pharbase
                  Data, (ii) is used or made available for use to promote or aid
                  in the promoting of any data or information which is not
                  derived from the Pharbase Data, or (iii) seeks to demonstrate
                  that the Pharbase Data, or any information derived therefrom,
                  is inferior to any other data, attempts to show any deficiency
                  in such Pharbase Data or information, or otherwise makes
                  statements detrimental to ST concerning such Pharbase Data or
                  information;
         e.       results in the reverse engineering or disassembling of any of
                  the Pharbase Data; or
         f.       enhances, benchmarks, validates, compares with, authenticates,
                  verifies, supplements, or modifies any data, products or
                  services of IMS or any other party except as expressly
                  provided in this Agreement.

<PAGE>

                          ARTICLE IV - RESTRICTED DATA

4.1      Either party may identify to the other party in writing certain
         elements of some or all of the Data which incorporates information
         licensed to a party of this Agreement by a third party, and which Data
         is subject to restrictions greater or different from the restrictions
         set forth in this Agreement ("Restricted Data"). In addition to the
         terms and conditions of this Agreement, the licensee hereunder agrees
         to treat each element of Restricted Data in accordance with the terms
         required by the third party. To the extent that any term of such a
         third party agreement then in effect is more restrictive concerning the
         use or disclosure of Restricted Data than the terms contained in this
         Agreement concerning the use or disclosure of Data, then the terms of
         such third party agreement shall control, but only with respect to the
         use or disclosure, as the case may be, of Restricted Data.

4.2      In the event a party hereto identifies Restricted Data pursuant to
         Paragraph 4.1 above as requiring an additional license and the licensee
         fails to maintain the requisite license with the applicable third party
         licensing such data which would permit licensee, at a minimum, a right
         to use the Restricted Data provided hereunder in the manner
         contemplated herein, then the licensor of such Data hereunder shall
         have no further requirement to provide such Restricted Data under the
         terms of this Agreement until such time as the receiving party obtains
         such a license.

4.3      Each party hereto shall use its reasonable commercial efforts to avoid
         third party restrictions which impair or restrict the rights of the
         other party to use IMS Data or Pharbase data, as the case may be, as
         otherwise permitted by the terms of Paragraph 2.3 and 3.3 respectively.
         For purposes of the preceding sentence, "reasonable commercial efforts"
         shall mean the use of reasonable commercial efforts by a party during
         the term of this Agreement to obtain amendments or new agreements with
         third parties so that such agreements do not impair or restrict a
         party's rights under the terms of this Agreement in it's use of Data
         licensed hereunder other than the applicable restrictions reflected in
         Articles II and III.

                           ARTICLE V - CONFIDENTIALITY

5.1      ST hereby acknowledges that the IMS Data are proprietary to IMS
         (collectively "IMS Confidential Information"), agree to protect the
         proprietary and confidential nature of such IMS Confidential
         Information and in connection therewith, will prohibit any access to or
         copying or disclosure of any of the IMS Confidential Information during
         the term of this Agreement and after termination of this Agreement,
         except (a) that access to and disclosure of IMS
         Confidential Information may be provided to those employees of ST, in
         connection with the uses permitted ST as described in Article II who
         require same to carry out such uses, and (b) as expressly permitted
         under Paragraphs 2.4 of this Agreement. ST and any such other persons
         who receive access to or disclosure of IMS

<PAGE>

         Confidential Information pursuant to the preceding sentence shall
         maintain the strict confidentiality of such IMS Confidential
         Information in the same manner as ST maintains the confidentiality of
         its own confidential information, and ST will not disclose such IMS
         Confidential Information except as expressly provided herein. In the
         event any of such other persons fail to comply with the confidentiality
         obligations contained in this Paragraph 5.1, ST shall promptly notify
         an appropriate representative of such person in writing of such
         failure, with a copy to IMS, within five business days after ST knows
         or suspects such failure. ST shall promptly provide IMS with a copy of
         any responses from such person to ST's notification. IMS shall have a
         right to bring an action as an intended third party beneficiary to
         enforce the terms and conditions of the agreement between ST and such
         person with respect to obligations of confidentiality. In the event IMS
         does not have rights as an intended third party beneficiary to bring an
         action as contemplated in this Paragraph 5.1, ST agrees to cooperate
         with IMS to pursue such third party for any material breach by such
         person of the terms of such agreement. ST agrees that it will not ever,
         either during the term of this Agreement or after its termination,
         assert that IMS Data are not, were not or will not be proprietary to
         IMS and subject to copyright held by IMS with the exception of elements
         of third party data which are proprietary to the respective third party
         and subject to copyright held by such third party.

5.2      IMS hereby acknowledges that the Pharbase Data are proprietary to ST
         (collectively "ST Confidential Information"), agree to protect the
         proprietary and confidential nature of such ST Confidential Information
         and in connection therewith, will prohibit any access to or copying or
         disclosure of any of the ST Confidential Information during the term of
         this Agreement and after termination of this Agreement, except (a) that
         access to and disclosure of ST Confidential Information may be provided
         to those employees of IMS, in connection with the uses permitted IMS as
         described in Article III who require same to carry out such uses, and
         (b) as expressly permitted under Paragraphs 3.4 of this Agreement. IMS
         and any such other persons who receive access to or disclosure of ST
         Confidential Information pursuant to the preceding sentence shall
         maintain the strict confidentiality of such ST Confidential Information
         in the same manner as IMS maintains the confidentiality of its own
         confidential information, and IMS will not disclose such ST
         Confidential Information except as expressly provided herein. In the
         event any of such other persons fail to comply with the confidentiality
         obligations contained in this Paragraph 5.2, IMS shall promptly notify
         an appropriate representative of such person in writing of such
         failure, with a copy to ST, within five business days after IMS knows
         or suspects such failure. IMS shall promptly provide ST with a copy of
         any responses from such person to IMS's notification. ST shall have a
         right to bring an action as an intended third party beneficiary to
         enforce the terms and conditions of the agreement between IMS and such
         person with respect to obligations of confidentiality. In the event ST
         does not have rights as an intended third party beneficiary to bring an
         action as contemplated in this Paragraph 5.2, IMS agrees to cooperate
         with ST to pursue such third party for any material breach by such
         person of the terms of such agreement. IMS agrees that it will not
         ever, either during the term of this Agreement or after its
         termination, assert that IMS

<PAGE>

         Data are not, were not or will not be proprietary to ST and subject to
         copyright held by ST with the exception of elements of third party data
         which are proprietary to the respective third party and subject to
         copyright held by such third party.

                   ARTICLE VI - REPRESENTATIONS AND WARRANTIES

6.1      IMS represents and warrants that it has the right and authority to
         license the IMS Data to ST under this Agreement. EXCEPT AS EXPRESSLY
         STATED IN THE PRECEDING SENTENCE AND APPENDIX 1, IMS MAKES NO WARRANTY
         OR REPRESENTATION, EXPRESS OR IMPLIED, AS TO THE IMS DATA (INCLUDING
         BUT NOT LIMITED TO ANY WARRANTY OF MERCHANTABILITY OF SUCH IMS DATA OR
         ITS FITNESS FOR ST'S PARTICULAR PURPOSE) AND FURTHER MAKES NO WARRANTY
         OR REPRESENTATION, EXPRESS OR IMPLIED, AS TO THE ACCURACY OR
         COMPLETENESS OF THE IMS DATA.

6.2      ST represents and warrants that it has the right and authority to
         license the Pharbase Data to IMS under this Agreement. EXCEPT AS
         EXPRESSLY STATED IN THE PRECEDING SENTENCE AND APPENDIX 1, ST MAKES NO
         WARRANTY OR REPRESENTATION, EXPRESS OR IMPLIED, AS TO THE PHARBASE DATA
         (INCLUDING BUT NOT LIMITED TO ANY WARRANTY OF MERCHANTABILITY OF SUCH
         PHARBASE DATA OR ITS FITNESS FOR IMS'S PARTICULAR PURPOSE) AND FURTHER
         MAKES NO WARRANTY OR REPRESENTATION, EXPRESS OR IMPLIED, AS TO THE
         ACCURACY OR COMPLETENESS OF THE PHARBASE DATA.

                      ARTICLE VII - LIMITATION OF LIABILITY

7.1      IMS's entire liability and ST's exclusive remedy for IMS's failure to
         abide by the accuracy and completeness requirements of Paragraph 2.2
         shall be for IMS to endeavor to correct, in accordance with IMS's then
         applicable operating procedures for data quality assurance, any such
         non-conformance which has been reported by ST to IMS in writing in a
         timely manner in accordance with the applicable EXHIBIT.
         Notwithstanding any injunctive relief which ST may be entitled to, IMS
         shall not be liable for any indirect, consequential, punitive,
         incidental or special damages to person, property or business which may
         be caused by any use, failure to provide or unavailability of IMS Data
         or any breach by IMS of its obligations hereunder (even if IMS has been
         advised of the possibility of such damages). Under no circumstances
         shall IMS's liability hereunder exceed the greater of (a) fifty
         thousand dollars ($50,000), or (b) the amount paid by ST to IMS
         hereunder in the immediately preceding twelve month period.

<PAGE>

7.2      ST's entire liability and IMS's exclusive remedy for ST's failure to
         abide by the accuracy and completeness requirements of Paragraph 3.2
         shall be for ST to endeavor to correct, in accordance with ST's then
         applicable operating procedures for data quality assurance, any such
         non-conformance which has been reported by IMS to ST in writing in a
         timely manner in accordance with the applicable EXHIBIT.
         Notwithstanding any injunctive relief which IMS may be entitled to, ST
         shall not be liable for any indirect, consequential, punitive,
         incidental or special damages to person, property or business which may
         be caused by any use, failure to provide or unavailability of Pharbase
         Data or any breach by ST of its obligations hereunder (even if ST has
         been advised of the possibility of such damages). Under no
         circumstances shall ST's liability hereunder exceed the greater of (a)
         fifty thousand dollars ($50,000), or (b) the amount paid by IMS to ST
         hereunder in the immediately preceding twelve month period.

                         ARTICLE VIII - TERM/TERMINATION

The term of this Agreement shall be for a three year period commencing on the
date first written above. Notwithstanding the foregoing, either party shall have
the right to terminate this Agreement on thirty (30) days advance written notice
to the other party:

8.1      if such other party becomes insolvent, voluntarily files a petition
         under any federal or state bankruptcy law for itself, has an
         involuntary petition filed under any federal, provincial or state
         bankruptcy law against it which is not removed within thirty (30) days
         of filing, ceases operations for at least thirty (30) days with the
         intent of winding up such party's business, or otherwise publicly
         announces the termination of its operations; or

8.2      upon the sale of such other party, whether by merger, consolidation,
         the sale of its stock or by the sale of all or substantially all of its
         assets to a Competing Company or any person or Entity controlling,
         controlled by or under common control with a Competing Company.

                           ARTICLE IX - FORCE MAJEURE

Neither party shall be deemed to have breached this Agreement or to be liable
for any damages caused by failure to perform or by delay in rendering
performance hereunder arising out of any occurrence or contingency beyond its
reasonable control, including but not limited to, (a) flood, earthquake, fire,
war, strikes, labor unrest, riot, civil commotion, power or communication line
failure, computer equipment failure or operational failure, (b) failure of
independent contractors under agreement with IMS to perform or a delay in such
performance, failures, delays or restrictions of sources from which information
or data is obtained, or failure of performance by Licensee, or (c)
prohibition(s) or restriction(s) imposed by applicable regulatory authority, the

<PAGE>

judgment, ruling or order of a court or agency of competent jurisdiction, or the
enactment of or change in any law or regulation.

<PAGE>

                        ARTICLE X - ADDITIONAL AGREEMENTS

10.1     IMS and ST each agree to keep the terms of this Agreement in confidence
         and not disclose them to any other Person, except for those terms of
         the Agreement required to be disclosed (i) pursuant to federal, state
         or national laws or regulations including securities laws and their
         related disclosure requirements, (ii) pursuant to judicial or
         arbitration orders and proceedings, (iii) as may be required to perform
         their obligations under this Agreement, or (iv) to each of IMS's and
         Licensee's legal and financial representatives who need to know such
         terms solely for the purpose of providing legal and financial advice to
         each such party, respectively. This provision shall not prohibit either
         party from disclosing the existence of this Agreement or that IMS is a
         data source.

10.2     Under no circumstances shall this Agreement be construed as placing any
         affirmative obligation on either party, express or implied, to collect
         or continue to collect any data or information from any third party
         from which the IMS Data or Pharbase Data is derived ("Source Data"). In
         the event a party hereto determines, in its sole judgment and
         discretion, to cease collecting any Source Data which will result in a
         substantial reduction in the amount of, or cessation in, the Data
         delivered hereunder, such party will provide written notice of such to
         the other party hereto at least ninety (90) days prior to the date on
         which such Source Data collection will cease, specifying the date or
         dates at which it will cease collecting such Source Data and the amount
         of Data that will be deleted as a result (the "Notice"). In such event,
         the party hereto giving such Notice shall incur no liability to the
         other party in connection therewith and, in the event the notifying
         party ceases to collect all of such Source Data, then this Agreement
         shall automatically terminate and be of no further force and effect
         upon the effective date of such cessation.

                            ARTICLE XI - ARBITRATION

11.1     Each party shall designate a project manager to coordinate such party's
         activities under this Agreement. Such project managers shall also, when
         necessary, confer in order to resolve problems or disputes that may
         arise in connection with each party's performance hereunder. If the
         project managers cannot resolve such problems or disputes, such
         problems or disputes shall be referred to each party's respective
         senior management for discussion and resolution.

11.2     Subject to Paragraph 11.4, any controversy or claim arising out of or
         relating to this Agreement, and which cannot be resolved in accordance
         with the procedure set forth in the preceding paragraph, shall be
         submitted to arbitration before a panel of three (3) arbitrators. The
         arbitrators shall be selected and the arbitration conducted in
         accordance with the _________________________. An award shall be
         conclusive and binding if concurred in by two (2) of the arbitrators,
         and judgment upon the award rendered by the arbitrators may be entered
         in any court having jurisdiction thereof. The arbitrators shall

<PAGE>

         be required to deliver a written decision setting forth their findings
         of fact and basis for their award. The arbitrators' award shall provide
         for the payment of the arbitrators' expenses and fees, together with
         other expenses incurred in the conduct of the arbitration proceeding
         other than legal fees and expenses. However, the arbitrators shall
         award the prevailing party reasonable attorneys' fees and other
         expenses incurred in the arbitration proceeding in the event that the
         arbitrators determine that either party acted in bad faith in
         connection with either asserting a claim or a defense in the
         arbitration proceeding itself.

11.3     The parties hereby agree to submit to the exclusive personal
         jurisdiction and venue of the _______________________________ for
         purposes of enforcing the agreement to arbitrate, providing provisional
         relief pending the award, and entering judgment on the award. If for
         any reason the aforesaid court does not have subject matter
         jurisdiction, the parties alternatively agree to submit to the
         exclusive personal jurisdiction and venue of the applicable court of
         the _____________________ for the foregoing purposes. Nothing contained
         in this paragraph shall preclude the arbitrators from granting, where
         appropriate, injunctive or other provisional relief pending a final
         award.

11.4     Notwithstanding the provisions of Paragraphs 11.2 and 11.3, any party
         hereto may pursue any provisional remedy (including but not limited to
         preliminary injunctive relief) to enforce its rights hereunder in the
         courts designated in Paragraph 11.3. The parties shall have the right
         to obtain such provisional injunctive relief from a court of law
         designated in Paragraph 11.3 pending the determination and award in the
         arbitration proceeding. The parties may seek injunctive relief either
         restraining certain conduct or mandating certain conduct. This
         Paragraph 11.4 shall not be deemed to limit the power of the
         arbitrators to grant any remedy or relief the arbitrators deem just or
         reasonable within the scope of this Agreement.

11.5     The parties agree that, immediately upon the designation of the
         arbitrators, they will request the arbitrators that they set an
         expedited schedule for the conduct of the arbitration proceeding such
         that the proceeding is concluded within six months of the date of the
         filing of a demand for arbitration and that an award shall be rendered
         within thirty (30) days of the conclusion of the proceeding.

                    ARTICLE XII - DATA PROTECTION OBLIGATIONS

         The parties agree to procure that those of their respective Affiliates
listed in Exhibits 1 and 2 hereto and which are established within the European
Union abide by the additional obligations set out in Appendix 1 as if they were
incorporated as terms and conditions of this Agreement.

<PAGE>

                          ARTICLE XIII - MISCELLANEOUS

13.1     The parties hereto are independent contractors engaged in the operation
         of their own respective businesses. Neither party is, or is to be
         considered as, the agent or employee of the other for any purpose
         whatsoever. Neither party has the authority to enter into contracts or
         assume any obligations for the other party or make any warranties or
         representations on behalf of the other party. Nothing in this Agreement
         shall be construed to establish a relationship of co-partners or joint
         venturers between the parties.

13.2     This Agreement (including the exhibits and Appendix 1) constitutes the
         entire understanding between the parties and supersedes all proposals,
         commitments, writings, negotiations and understandings, oral and
         written, and all other communications between the parties relating to
         the subject matter of this Agreement.

13.3     Either party may assign all or any portion of this Agreement to an
         entity which is then an Affiliate and any such Affiliate may assign all
         or any portion of this Agreement to an entity which is then a
         Affiliate; provided, however, that any such assignment shall not
         relieve the assigning party of its obligations under this Agreement.
         This Agreement may not be assigned from ST to any other person or
         Entity, whether by assignment by ST, by operation of law or otherwise
         without the prior written consent of IMS which consent shall not be
         unreasonably withheld. The sale or transfer of a majority of the
         outstanding shares of Licensee, or the merger or consolidation of ST
         with any other person or Entity, shall be deemed an attempt by ST to
         assign its interests in this Agreement which shall first require the
         prior written consent of IMS. Any assignment not expressly permitted
         under this Paragraph 13.3 or which has not received the written consent
         of the other party if required herein shall be void.

13.4     Should any part, term or condition hereof be declared illegal or
         unenforceable or in conflict with any other law, the validity of the
         remaining portion or provisions of this Agreement shall not be affected
         thereby, and the illegal or offensive portions of this Agreement shall
         be and hereby are redrafted to conform with applicable law in a manner
         which is consistent with the original spirit and intent embodied in the
         original executed copy of this Agreement, while leaving the remaining
         portions of this Agreement intact.

13.5     The waiver by either party of a breach or violation hereof or remedy
         provided herein shall not operate as or be construed to be a waiver of
         any subsequent breach or violation hereof.

13.6     This Agreement (save for Appendix 1) shall be governed by and construed
         in accordance with the laws of the __________________________ without
         giving effect to principles of conflicts of law.

<PAGE>

13.7     Nothing in this Agreement is intended to benefit and shall not be
         deemed to benefit any person who is not a party hereto or to create any
         third party beneficiary rights.

13.8     All notices pertaining to this Agreement or the performance of either
         party hereunder shall be sufficient if in writing and sent by DHL or
         other similar overnight courier service with receipted delivery
         addressed to the other party at the address shown below or to such
         other address as a party hereto shall supply to the other in writing:

                  If to IMS:

                           IMS HEALTH
                           7 Harewood Avenue
                           London, NW1 6JB
                           England
                           Attention:  President, European Region

                  With a copy to:

                           IMS HEALTH
                           7 Harewood Avenue
                           London, NW1 6JB
                           England
                           Attention:  Law Department

                  If to Licensee:
                           Synavant Inc.
                           3445 Peachtree Road, N.E.
                           Suite 1400
                           Atlanta, GA 30326
                           Attention:  President

         Such notice shall be effective upon receipt by the other party.

13.9     Neither party may under any circumstances utilize the name, trademarks,
         or tradenames of the other, or any names, trademarks, or tradenames so
         similar as likely to cause confusion, without the prior written notice
         to, and express written approval of, the other. Notwithstanding the
         preceding sentence, each party shall have a right to identify to any
         person or Entity that the other party is a supplier and licensee of
         Data hereunder.

<PAGE>

13.10    Paragraph headings herein are for convenience only and do not control
         or affect the meaning or interpretation of any terms or provisions of
         this Agreement.

                               ARTICLE XIV - FEES

         The annual fee payable by IMS for the services described in this
Agreement for each Contract Year shall be one million five hundred thousand
dollars ($1,500,000). ST shall invoice one quarter of the annual fee on a
quarterly basis in advance (i.e., ST shall invoice three hundred seventy-five
thousand dollars ($375,000) on or about September 1st, December 1st, March 1st,
and June 1st of each Contract Year). IMS shall pay the amount of each invoice
from ST within thirty (30) days from receipt of invoice by IMS. In no event
shall IMS deduct or set-off any amount(s) against any amount(s) owed to ST under
this Agreement without ST's prior written consent. If IMS fails to timely pay
any amount in accordance with the terms of this Agreement, IMS shall pay in
addition to the invoice amount, interest at the rate of eighteen percent (18%)
per annum on the unpaid balance beginning thirty-five (35) days from the date of
the invoice until such amounts are paid. In addition to any fees which IMS
agrees to pay, IMS shall have the exclusive responsibility for and agrees to pay
all applicable governmental sales, use, added value, ad valorem or other similar
taxes, duties, fees, levies or other governmental charges now in force or
enacted in the future, except for taxes based on ST's income.

         IN WITNESS WHEREOF, the parties have executed this Agreement on the
date first written above.

IMS Health Incorporated:                Synavant Inc.:

By:__________________________           By:________________________________

Name:________________________           Name:______________________________

Title:_______________________           Title:_____________________________

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00014-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00014-of-00352.parquet"}]]